ANCOVA approach for shelf life analysis of stability study of multiple factor designs

Journal of Biopharmaceutical Statistics

Volumn 13, Issue 3, 2003, Pages 375-393

  Tsong, Yi ^a   Chen, Wen Jen ^b   Chen, Chi Wan ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Center for Drug Evaluation and Research   (United States)

Author keywords

ANCOVA; Multiple factor design; Shelf life; Stability study

Indexed keywords

DRUG;

ANALYTIC METHOD; ARTICLE; DATA ANALYSIS; DRUG STABILITY; FACTORIAL ANALYSIS; LINEAR REGRESSION ANALYSIS; MODEL; MULTIVARIATE ANALYSIS OF COVARIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHELF LIFE;

DRUG STABILITY; DRUG STORAGE; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; TIME FACTORS;

EID: 0041663355     PISSN: 10543406     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIP-120022761     Document Type: Article

References (28)

1. Ahn, H., Chen, J., Lin, T. D. (1997). A two-way analysis of covariance model for classification of stability data. Biom. J. 39(5):559-576.
2. Asano, C. (1960). Tests due to pooling data through preliminary test on biological direct assay. Bull. Math. Stat. 9:25-39.
3. Bancroft, T. A. (1944). On biases in estimation due to the use of preliminary tests of significance. Ann. Math. Stat. 15:190-204.
4. Bancroft, T. A. (1964). Analysis and inference for incompletely specified models involving the use of preliminary tests of significance. Biometrics 20(3):427-442.
5. Chambers, D. (1996). Matrixing/bracketing. US industry views. In: Proceedings from EFPIA Symposium: Advanced Topics in Pharmaceutical Stability Testing Building on the ICH Stability Guideline. EFPIA, Brussels.
6. Chen, C. (1996). US FDA's perspective of matrixing and bracketing. In: Proceedings from EFPIA Symposium: Advanced Topics in Pharmaceutical Stability Testing Building on the ICH Stability Guideline. EFPIA, Brussels.
7. Chen, W. J., Tsong, Y. (2003). Significance level for stability polling test: a simulation study. J. Biopharm. Stat., 13(3):355-374.
8. Chen, J., Ahn, H., Tsong, Y. (1997). Shelf life estimation for multi-factor stability studies. Drug Inf. J. 31(2):573-587.
9. Chow, S. C., Liu, J. P. (1995). Statistical Design and Analysis in Pharmaceutical Sciences. New York, NY, USA: Marcel Dekker.
10. CPMP. (1996). Draft Guideline: Reduced Stability Testing - Bracketing and Matrixing. CPMP/QWP/157/1996. London: European Medicines Evaluation Agency.
11. Draft ICH Consensus Guideline. (2001). Q1E Stability Data Evaluation. Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, www.fda.gov/cder/guidance/4983dft.pdf.
12. Fairweather, W., Lin, T. D., Kelly, R. (1995). Regulatory, design, and analysis aspects of complex stability studies. J. Pharm. Sci. 84(11):1322-1326.
13. FDA. (1987). Guidelines for Submitting Documentation for the Stability of Human Drugs and Biologics. Rockville, MD: USA Food and Drug Administration, Center for Drugs and Biologics.
14. Golden, M. H., Cooper, D., Riebe, M., Carswell, K. (1996). A matrixed approach to long-term stability testing of pharmaceutical products. J. Pharm. Sci. 86:240-244.
15. Guidance for Industry: ICH. (2001). Q1A(R) Stability Testing of New Drug Substances and Products. Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, www.fda.gov/cder/guidance/4282fnl.pdf.
16. Guidance for Industry: ICH. (2003). Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products. Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, www.fda.gov/cder/guidance/4985fnl.pdf.
17. Helboe, P. (1992). New designs for stability testing programs: matrix or factorial designs. Authorities viewpoint on the predictive value of such studies. Drug Inf. J. 26:629-634.
18. Johnson, J. P., Bancroft, T. A., Han, C. P. (1977). A pooling methodology for regressions in prediction. Biometrics 33:57-67.
19. Larson, H. J., Bancroft, T. A. (1963). Sequential model building for prediction in regression analysis, I. Ann. Math. Stat. 34:231-242.
20. Lin, T. D. (1994). Applicability of matrix and bracket approach to stability study design. In: Proceedings of Biopharm. Section. Amer. Stat. Assoc., pp. 142-147.
21. Lin, T.-Y. D., Tsong, Y. (1991). Determination of significance level for pooling data in stability studies. In: Proceedings of Biopharm. Section. Amer. Statist. Assoc., pp. 195-201.
22. Lin, K. K., Lin, T. D., Kelly, R. E. (1993). Stability of drugs. In: Buncher, C. R., Tsay, J. Y., eds. Statistics in the Pharmaceutical Industry. 2nd ed. New York, NY, USA: Marcel Dekker, pp. 419-444.
23. Munden, R. (1996). Matrixing and bracketing in stability testing - a view from European industry. In: Proceedings from EFPIA Symposium: Advanced Topics in Pharmaceutical Stability Testing Building on the ICH Stability Guideline. EFPIA, Brussels.
24. Nakagaki, P. (1990). Matrixing and bracketing of solid oral dosage forms for thermal stability studies. APPS Annual Meeting. Las Vegas, NV.
25. Nordbrock, E. (1992). Statistical comparison of stability study designs. J. Biopharm. Stat. 2:91-113.
26. Ruberg, S. J., Stegeman, J. W. (1991). Pooling data for stability studies: testing the equality of batch degradation slopes. Biometrics 47:1059-1069.
27. Terada, S. (1996). Japanese industries views on matrixing and bracketing. In: Proceedings from EFPIA Symposium: Advanced Topics in Pharmaceutical Stability Testing Building on the ICH Stability Guideline. EFPIA, Brussels.
28. Yoshioka, S., Aso, Y., Kojima, S. (1996). Statistical evaluation of shelf-life of pharmaceutical products estimated by matrixing. Drug Stab. 1:147-151.